South Africa has received its first batch of the long-acting HIV prevention injection Lenacapavir, with 37 920 doses now in the country. The Department of Health confirmed the development this week, signalling a shift in how HIV prevention could be delivered, particularly in high-burden provinces like Gauteng. The rollout matters now as health officials look to improve adherence and reduce new infections using alternatives to daily medication.
The six-monthly injectable is expected to form part of South Africa’s broader HIV prevention strategy, with a national rollout plan set to be announced in the coming weeks.
ALSO READ: Gauteng Load Reduction Schedule for 7 to 13 April 2026: Full Timetable and Affected Areas
South Africa Introduces Long-acting HIV Prevention Injection
The Department of Health said Lenacapavir will be integrated into its existing HIV prevention programmes as part of a people-centred approach aligned with the Global AIDS Strategy for 2026 to 2030.
According to spokesperson Foster Mohale, the injection is designed to expand prevention options and reach individuals who face barriers to current HIV prevention methods.
“This is part of integrated, differentiated and people-centred HIV prevention services which offer new hope for people who face barriers to existing HIV prevention methods,” Mohale said.
The department emphasised that the injectable will complement, rather than replace, existing prevention tools.
Six-monthly Dosing Expected to Improve Adherence
Lenacapavir is administered as a subcutaneous injection twice a year, significantly reducing the need for daily oral prevention medication.
Health officials say this feature could improve adherence among groups that struggle to maintain daily treatment routines.
Priority groups identified include:
- Adolescent girls and young women
- Sex workers
- Men who have sex with men
- Individuals at high risk of HIV exposure
According to the department, improving adherence is central to reducing infection rates, particularly in densely populated provinces such as Gauteng.
Rollout Details to be Announced by Health Minister
The Department of Health said a phased rollout plan will be confirmed soon, with an official launch expected to be led by Health Minister Dr Aaron Motsoaledi.
While details are still pending, officials indicated that:
- High-risk populations will be prioritised
- Rollout will be phased across provinces
- Public healthcare facilities will play a central role
The department has not yet confirmed timelines or specific distribution sites.
SAHPRA Approval Places South Africa at the Forefront of HIV Prevention
Lenacapavir was registered by the South African Health Products Regulatory Authority in October 2025 under the brand name Sunlenca.
This made South Africa the first country in Africa to approve the long-acting injectable for HIV prevention.
Health experts say this positions the country at the forefront of adopting new prevention technologies, particularly as global efforts intensify to end AIDS as a public health threat by 2030.
Clinical trial data has shown high levels of effectiveness, with significant reductions in new infections among participants.
Why Lenacapavir is Considered a Major HIV Prevention Breakthrough
Health officials describe Lenacapavir as a potential “game changer” due to its long-acting nature and simplified dosing schedule.
Key advantages include:
- Reduced reliance on daily medication
- Improved adherence rates
- Lower risk of missed doses
- Expanded access for hard-to-reach populations
Mohale said the injectable represents one of the most significant advances in HIV prevention in recent years.
However, experts note that the success of the programme will depend on effective rollout and equitable access across provinces.
What This Means for Gauteng Residents
For Gauteng residents, the introduction of Lenacapavir could change how HIV prevention services are accessed.
The province continues to carry a high HIV burden, particularly among young people and urban communities.
The new injection means:
- Fewer clinic visits compared to daily medication
- Greater flexibility in prevention options
- Potential improvement in long-term adherence
- Expanded access for vulnerable groups
However, access will depend on how quickly the rollout is implemented within Gauteng’s healthcare system.
FAQ: Lenacapavir HIV prevention injection
What is Lenacapavir?
It is a long-acting injectable used for HIV prevention and treatment, administered twice a year.
Is Lenacapavir a vaccine?
No. It is a preventive medication, not a vaccine.
Who will receive it first?
High-risk groups will be prioritised during the initial rollout phase.
When will it be available?
The Department of Health has not yet confirmed an official rollout date.
Why is it important?
It offers an alternative to daily HIV prevention pills, which may improve adherence and reduce new infections.
What Happens Next
The Department of Health is expected to release further details on rollout timelines and distribution plans in the coming weeks.
Health authorities will also monitor early uptake and outcomes as the programme is introduced across provinces.
The success of Lenacapavir in South Africa may influence future HIV prevention strategies as the country works toward its 2030 targets.
